1. Home
  2. BCYC vs KREF Comparison

BCYC vs KREF Comparison

Compare BCYC & KREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCYC
  • KREF
  • Stock Information
  • Founded
  • BCYC 2009
  • KREF 2014
  • Country
  • BCYC United Kingdom
  • KREF United States
  • Employees
  • BCYC N/A
  • KREF N/A
  • Industry
  • BCYC Biotechnology: Pharmaceutical Preparations
  • KREF Real Estate Investment Trusts
  • Sector
  • BCYC Health Care
  • KREF Real Estate
  • Exchange
  • BCYC Nasdaq
  • KREF Nasdaq
  • Market Cap
  • BCYC 565.5M
  • KREF 623.9M
  • IPO Year
  • BCYC 2019
  • KREF 2017
  • Fundamental
  • Price
  • BCYC $8.76
  • KREF $8.25
  • Analyst Decision
  • BCYC Buy
  • KREF Buy
  • Analyst Count
  • BCYC 11
  • KREF 6
  • Target Price
  • BCYC $22.91
  • KREF $10.71
  • AVG Volume (30 Days)
  • BCYC 284.7K
  • KREF 812.8K
  • Earning Date
  • BCYC 10-31-2025
  • KREF 10-21-2025
  • Dividend Yield
  • BCYC N/A
  • KREF 11.74%
  • EPS Growth
  • BCYC N/A
  • KREF N/A
  • EPS
  • BCYC N/A
  • KREF N/A
  • Revenue
  • BCYC $19,281,000.00
  • KREF $62,012,000.00
  • Revenue This Year
  • BCYC N/A
  • KREF $23.96
  • Revenue Next Year
  • BCYC N/A
  • KREF N/A
  • P/E Ratio
  • BCYC N/A
  • KREF N/A
  • Revenue Growth
  • BCYC N/A
  • KREF N/A
  • 52 Week Low
  • BCYC $6.10
  • KREF $8.27
  • 52 Week High
  • BCYC $25.39
  • KREF $12.33
  • Technical
  • Relative Strength Index (RSI)
  • BCYC 56.40
  • KREF 30.05
  • Support Level
  • BCYC $7.65
  • KREF $8.41
  • Resistance Level
  • BCYC $8.75
  • KREF $8.83
  • Average True Range (ATR)
  • BCYC 0.45
  • KREF 0.24
  • MACD
  • BCYC -0.03
  • KREF -0.01
  • Stochastic Oscillator
  • BCYC 55.56
  • KREF 3.11

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

Share on Social Networks: